Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methoserpidine
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methoserpidine is a synthetic yohimban alkaloid and an antihypertensive drug related to reserpine. It was used primarily in the 1960s for the treatment of arterial hypertension. Methoserpidine acts as a sympatholytic agent (antagonist of α-adrenergic vasoconstriction), similar to reserpine, and is considered an isomer or close analog of reserpine. It was initially reported to have fewer central nervous system side effects compared to reserpine[1][3][5][7]. Its mechanism involves depletion of catecholamines from peripheral sympathetic nerve endings.
- Brand names
- DecaserpylNeoserpinReserteneTenserpina
- Other names
- methoserpidine
02
Targets
VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on methoserpidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methoserpidine.